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Abstract
Background: The International Classification of Functioning, Disability and Health (ICF) aims to comprehensively
describe the ways in which a person’s health condition affects their life. This study aimed to contribute to the
development of an ICF core set for gout through patient opinion derived from focus groups and interviews.
Methods: We conducted a secondary qualitative analysis of data from three studies investigating the patient
experience of gout. In total there were 30 individual interviews and 2 focus groups (N = 17) comprising 47
participants. We conducted thematic analysis of the textual data to extract meaning units, which were then linked
to the ICF.
Results: A large number of ICF categories were relevant to patients with gout. Participants mentioned 93 third
level categories, 17 of which were mentioned by more than 50% of patients. The most references for a single
category was for b280, Sensation of pain, followed by personal factors (not yet categorised by the ICF). The most
participants mentioned the environmental factor e355, Health professional support, followed by b280, Sensation of
pain.
Conclusion: The categories identified in this study as relevant to patients with gout highlight the severe pain
associated with this disease, the impact on mobility and corresponding life areas. The roles of health professional
support, medication, and personal attitudes to disease management are also reflected in the data. These results will
contribute to the development of the ICF core set for gout.
Keywords: Gout, International classification of functioning, Disability and health, World Health Organisation, Patient
outcome assessment, Qualitative research
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Background
Once known as the ‘rich man’s disease’, gout is increas-
ingly common among older men, where it is the most
common inflammatory joint disease [1]. Gout is a meta-
bolic disease caused by high levels of urate, forming crys-
tals that deposit in joints and periarticular tissues, leading
to painful and debilitating arthritis [2]. Flares are intermit-
tent but markedly painful, and as the disease progresses
may become more frequent and tophi (deposits of mono-
sodium uric acid crystals) may develop [2].
For the sufferer, gout attacks (or ‘flares’) are not only
painful but disabling, leading to a marked decrease in
mobility and impacting on many life areas, such as em-
ployment [3]. Yet previous means of assessing disability
in gout have been problematic because of its episodic
nature, and because measures may not adequately reflect
the impact of gout on lower limb functioning and mobil-
ity or sufficiently capture the breadth of the disease im-
pact as experienced by the patient [4, 5].
The International Classification of Functioning, Dis-
ability and Health is the World Health Organisation
(WHO) framework for the conceptual understanding of
health and disability [6]. It classifies the impacts of a dis-
ease related to its effect on body functioning, body struc-
tures or activities and participation, impacts which may
be mediated by the facilitators or barriers offered by a
person’s physical, social and cultural environment. The
complete ICF contains over 1000 fourth level categories
[6]. This provides a comprehensive overview of the
health of an individual but only some of these will be
relevant to a given disease.
The development of ICF core sets is intended to pro-
vide a concise set of categories of functioning related to
a particular condition, leading to tools for research and
practice that have global applicability [7]. Developing
these measures requires input from both health profes-
sionals and sufferers of the disease. This paper supple-
ments the research of Kool et al. by providing a patient
perspective of the impact of gout on various areas of life
as described by the ICF [8]. A core-set of ICF categories
relevant to people with gout is highly useful to ensure
adequate content coverage of tools and instruments to
evaluate outcomes, including patient-reported outcomes,
in clinical care, intervention studies and other outcomes
research.
Methods
This study was a secondary analysis of data collected by
three primary qualitative studies, conducted in the
United States [9], New Zealand [10] and Spain (not yet
published). These studies are described in more detail
below. There were 47 participants in total comprising 30
individual interviews and two focus groups with a total
of 17 participants.
This study is a qualitative ‘amplified supplementary
analysis’; more than one data set has been combined to
allow an analysis of an aspect that was partially ad-
dressed in the primary studies – namely patient experi-
ence of gout – but that supplements these conclusions
by including a new factor, the ICF [11]. Each individual
study received approval from the relevant research ethics
committee or Institutional Review Board.
New Zealand transcripts
Ten individual interviews with male gout patients were
obtained from a study based in South Auckland, NZ
[10]. The authors used purposive sampling to ensure a
range of ethnicities and experiences, conducting semi-
structured interviews using a grounded theory method-
ology to explore participant experiences of gout, their
understanding of the disease and attitude toward it and
its treatment. Questions were motivated an overall ques-
tion of “Why is gout so severe in Counties Manukau?”
These included questions about the history of the pa-
tients’ lifetime experience of gout and pre-disease-onset
knowledge of gout.
United States transcripts
Transcripts were obtained from 20 individual interviews
with gout patients (male = 12, female = 8) in Baltimore,
New Orleans and St. Louis, USA [9]. Sampling was pur-
posive to ensure a range of characteristics, and partici-
pants were recruited through their rheumatologist or
primary care physician. The main motivation for this
study was to understand the patient experience of gout
in order to better measure clinical study endpoints or to
guide development of a gout-specific outcome measure
for clinical trial use. The interviews followed a detailed
interview guide; the first half of the interview used open-
ended questions to explore the participant’s experience
of the disease with a main focus on symptoms and bur-
den, and the second half involved completion and as-
sessment of patient outcome measures, the Heath
Assessment Questionnaire – Disability Index and Gout
Assessment Questionnaire ‘overall concern’ domain.
Each interview was on average 1.5 h long.
Spanish transcripts
Two focus group transcripts were obtained from a study
in Barcelona, Spain. The first focus group was purpos-
ively sampled to give a range of age, gender and disease
characteristics and had 11 participants (M = 8, F = 3).
Participants in the second focus group (N = 6; M = 5 F =
1) were recruited from an outpatient clinic and were se-
lected consecutively. Each focus group lasted about 2 h
and 30min. Discussion prompts included: what causes
gout, how gout was diagnosed, symptoms of gout, effects
in daily life, experience of treatments, relationships with
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health professionals, and societal concepts of gout. Focus
group discussion was in Castillian and translated into
English by a multilingual, native Italian speaker.
Analysis
Qualitative data analysis followed the process of mean-
ing condensation [12]. Familiarity with the transcripts
from each study was established and meaning units were
identified in the data [12]. Concepts were identified
within each meaning units and were grouped into simi-
lar concepts using the analysis software NVivo 11
(NVivo qualitative data analysis Software; QSR Inter-
national Pty Ltd. Version 11, 2016). For instance, the
comment, “You can’t walk on it, you know. Even to have
a – the sheet on the bed to touch it is painful” contains
the concepts ‘difficulty walking any distance’ and ‘pain
caused from minimum sensation’. An initial sub-set of 2
transcripts was coded by both coders to establish inter-
rater reliability.
Each concept was then linked to the most appropriate
ICF category according to established linking rules [13,
14]. The ICF is divided into chapters, or ‘first level’ cat-
egories, which sub-divide the four separate concepts of
body functions, body structures, activities and participa-
tion, and environmental factors. Each chapter consists of
a number of ‘second level’ headings, which are made up
of ‘third level’ and then the most detailed ‘fourth level’
categories (6). Concepts were linked to the most relevant
fourth level ICF category if possible. If no such category
was appropriate, they were linked to a third level cat-
egory, or in some instances, a second level category.
There were some concepts that were not able to be
linked to any ICF categories, which were coded as non-
definable.
As an example, the concept ‘difficulty walking any dis-
tance’ was linked to d4508 Walking, other specified --
any distance under the third level category, Walking.
‘Pain caused from minimum sensation’ was linked to
b2702 Sensitivity to pressure, under the third level cat-
egory, Sensory functions related to temperature and other
stimuli. After concepts had been linked to the ICF the
second researcher (WT) confirmed the accuracy of link-
age decisions in a random subset (10%) of the linked
categories.
Results
In total 4897 meaning units were identified across all
transcripts. These were grouped into 396 initial con-
cepts. These concepts were linked to 93 third level cat-
egories of the ICF. Of these, 17 were in the body
functions chapter, 5 in the body structures chapter, 35
in the activities and participation chapter, and 34 in the
environmental factors chapter, 15 of which denoted fa-
cilitators or positive attributes of the environment, and
the remaining 19 of which denoted negative attributes
or barriers. See Table 1 for a comprehensive overview.
In addition, 27 initial concepts were linked to the con-
cept of personal factors, which are not yet categorised by
the ICF. These were grouped into four main areas: indi-
vidual attitudes to disease and its management (60% of
the references in this category), health literacy (19%),
family experience of gout (12%) and negative attitudes to
seeking care (8%).
There were several concepts were not definable by the
ICF: co-morbidities, association with ethnicity, commu-
nity visibility of gout, features of onset, physical (non-
dietary) triggers, and certain approaches to managing
pain and disease. Tophi were included as a non-
definable physical factor.
There were 17 categories mentioned by at least 50% of
participants; these categories largely correspond to those
that received the greatest number of mentions (Table 2).
The top five categories mentioned by the most number
of participants were:
e355 Health professionals ++ (98% of participants), eg
BM-02: In – one night, it was so severe, I had to go to the
hospital, because I didn’t have any medicine. And I went
on – went to XXXX Hospital. They gave me three tablets
of Cortisine (sic) – Cortisine (sic) – what – how you pro-
nounce it – and told me to go see my regular private-
care physician, which was Dr. XXXX. And she gave me
the same thing. And I’ve been taking it for the last 2
weeks, but I’m kind of over this bout a – at this time.
d570 Looking after one’s health -- negative impacts
(96%), eg BM-03: It g – it got – it got a little better, but
even though I don’t eat the beef, I don’t eat the steak,
guess what? It just falls on you. Something just – just falls
me on you, you know, one way or the other. You know, I
think it’s just – it’s – it’s just falls, you know what I’m
saying? Because – b280 Sensation of pain (96%), eg BM-
04: Because that’s what overrides everything else. I mean
the swelling is one thing. I mean you can kind of deal
with that. The – the - uh, the temp – you know the heat-
ing up of the joint, you can kind of deal with that, but
the excruciating pain is – you know, dominates all that.
e110 Products or substances for personal consumption
– facilitator, and personal factors. Eg SUBJECT: Well he
always tells me don’t eat this, don’t eat that, take these
pills because they are the ones and he tried to put me on
Allopurinol and they did not work because I was had an
attack through it so his only alternative was to give me
these pills Colchicine and of course it was down the track
through other friends of mine that told me what Prednis-
one can do to you in the end and it will start eating into
your bones or something like that and now I am starting
to wake up to that. But at the end of the day it was fixing
the pain and it was no fault of his, if I wanted some I
was going to have to get some for the pain and all that.
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Table 1 Linked ICF categories and number of references by data source
ICF Category US NZ Spain Total
Body functions
b body functions 4 8 8 20
b126 Temperament and personality functions 126 10 6 142
b130 Energy and drive functions 32 1 0 33
b134 Sleep functions 56 0 2 58
b140 Attention functions 7 1 0 8
b152 Emotional functions 117 11 3 131
b180 Experience of self and time functions 9 0 0 9
b265 Touch function 22 2 1 25
b270 Sensory functions related to temperature and other stimuli 81 12 7 100
b280 Sensation of pain 413 40 44 497
b298 Sensory functions and pain, other specified -- sensation of paralysis 16 0 0 16
b298 Sensory functions and pain, other specified -- sensation of weakness 10 0 0 10
b525 Defecation functions 7 5 1 13
b535 Sensations associated with the digestive system 2 3 0 5
b710 Mobility of joint functions 55 3 7 65
b755 Involuntary movement reaction functions 5 0 0 5
b770 Gait pattern functions 34 4 6 44
Activity and participation
d activities 37 1 3 41
d230 Carrying out daily routine 28 1 0 29
d240 Handling stress and other psychological demands 5 2 3 10
d298 General tasks and demands, other specified -- planning
to undertake activities
11 0 0 11
d4 mobility 63 5 8 76
d410 Changing basic body position 102 5 0 107
d415 Maintaining a body position 38 2 1 41
d420 Transferring oneself 28 3 0 31
d430 Lifting and carrying objects 10 0 0 10
d440 Fine hand use 35 1 0 36
d445 Hand and arm use 25 1 1 27
d450 Walking 148 16 8 172
d455 Moving around 33 3 2 38
d460 Moving around in different locations 24 5 4 33
d470 Using transportation 15 2 1 18
d480 Riding animals for transportation 0 1 0 1
d510 Washing oneself 27 1 2 30
d520 Caring for body parts 21 0 0 21
d530 Toileting 1 0 0 1
d540 Dressing 75 3 3 81
d550 Eating 8 0 0 8
d570 Looking after one’s health -- negative impacts 98 74 65 237
d570 Looking after one’s health -- positive impacts 105 59 28 192
d620 Acquisition of goods and services 33 0 0 33
d630 Preparing meals 15 0 0 15
d640 Doing housework 42 0 0 42
d660 Assisting others 10 0 0 10
d750 Informal social relationships 2 0 2 4
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Table 1 Linked ICF categories and number of references by data source (Continued)
ICF Category US NZ Spain Total
d760 Family relationships 7 8 5 20
d770 Intimate relationships 3 0 0 3
d845 Acquiring, keeping and terminating a job 4 3 1 8
d850 Remunerative employment 67 22 9 98
d870 Economic self-sufficiency 1 2 1 4
d920 Recreation and leisure 34 17 12 63
d930 Religion and spirituality 14 0 0 14
Environmental factors
e110 Products or substances for personal consumption -- barrier 49 29 24 102
e110 Products or substances for personal consumption -- facilitator 170 42 32 244
e115 Products and technology for personal use in daily living 42 0 2 44
e120 Products and technology for personal indoor and outdoor
mobility and transportation
64 3 3 70
e225 Climate 1 2 0 3
e310 Immediate family -- 0 3 2 5
e310 Immediate family ++ 61 26 8 95
e320 Friends -- 0 1 0 1
e320 Friends ++ 2 3 1 6
e325 Acquaintances, peers, colleagues, neighbours and community
members ++
4 0 1 5
e330 People in positions of authority -- 0 2 0 2
e330 People in positions of authority ++ 2 6 0 8
e355 Health professionals -- 3 30 23 56
e355 Health professionals ++ 92 78 51 221
e355 Health professionals 00 2 3 5 10
e398 Support and relationships, other specified -- absence due to
living alone
1 0 0 1
e398 Support and relationships, other specified -- burden of care for
immediate family
1 6 0 7
e398 Support and relationships, other specified -- emotional impact
for family members
3 3 1 7
e410 Individual attitudes of immediate family members -- 0 3 1 4
e410 Individual attitudes of immediate family members ++ 6 7 1 14
e420 Individual attitudes of friends ++ 2 0 0 2
e420 Individual attitudes of friends 00 1 2 0 3
e425 Individual attitudes of acquaintances, peers, colleagues,
neighbours and community members --
0 3 2 5
e430 Individual attitudes of people in positions of authority -- 0 0 1 1
e430 Individual attitudes of people in positions of authority ++ 3 2 0 5
e450 Individual attitudes of health professionals -- 0 1 0 1
e450 Individual attitudes of health professionals ++ 1 2 0 3
e460 Societal attitudes -- 1 18 10 29
e460 Societal attitudes 00 or ++ 1 4 0 5
e465 Social norms, practices and ideologies 10 15 2 27
e498 Attitudes, other specified -- restauranteurs 0 0 2 2
e570 Social security services, systems and policies ++ 2 0 0 2
e580 Health services, systems and policies -- 6 11 6 23
e580 Health services, systems and policies ++ 2 8 8 18
Body structures
s710 Structure of head and neck region 1 0 0 1
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Categories from 17 of the 30 first level chapters of the
ICF were mentioned by participants (Table 3). The Body
Structures chapter was the least common, with only 5%
of references coded to categories in this chapter; most of
this related to Structures Related to Movement. The
other chapters of Body Functions, Activities and
Participation, and Environmental Factors were split
roughly evenly, with 30, 39 and 26% of total references
respectively (Table 4). In these first level categories, Sen-
sory Functions and Pain was the most common in the
category of Body Functions; the majority of this was re-
lated to b280 Sensation of pain (77% of the references
Table 1 Linked ICF categories and number of references by data source (Continued)
ICF Category US NZ Spain Total
s730 Structure of upper extremity 27 3 2 32
s750 Structure of lower extremity 110 4 8 122
s798 Structures related to movement, other
specified -- unspecified joints
26 2 1 29
s810 Structure of areas of skin 20 2 4 26
nd-ph -- tophi 1 4 11 16
personal factors 189 164 86 436
total 3071 829 542 4439
Table 2 Top 20 most mentioned ICF categories (ranked in order of most to fewest mentions)
ICF category US (n = 20) NZ (N = 10) Spain (n = 17) Total
number of
instances
(% of
participants)
Number of
instances (% of
participants)
Median number
of instances per
participant
Number of
instances (% of
participants)
Median number
of instances per
participant
Number of
instances (% of
participants)
b280 Sensation of pain 413 (100) 18.5 40 (100) 4 44 (88) 497 (96)
Personal factors 189 (100) 6.5 164 (100) 14 86 (82) 439 (94)
e110 Products or substances for
personal consumption -- facilitator
170 (95) 7 42 (100) 4.5 32 (88) 244 (94)
d570 Looking after one’s health --
negative impacts
98 (95) 5 74 (100) 7 65 (94) 237 (96)
e355 Health professionals ++ 92 (100) 5 78 (100) 8 51 (94) 221 (98)
d570 Looking after one’s health --
positive impacts
105 (85) 5 59 (100) 3.5 28 (76) 192 (85)
d450 Walking 148 (100) 7 16 (80) 1 8 (29) 172 (70)
b126 Temperament and personality
functions
126 (95) 6.5 10 (60) 1 6 (41) 142 (68)
b152 Emotional functions 117 (85) 5.5 11 (80) 1 3 (12) 131 (57)
s750 Structure of lower extremity 110 (80) 5.5 4 (20) 0 8 (35) 122 (51)
ad410 Changing basic body position 102 5 0 107
e110 Products or substances for
personal consumption -- barrier
49 (75) 2 29 (90) 3 24 (65) 102 (74)
b270 Sensory functions related to
temperature and other stimuli
81 (65) 2.5 12 (60) 1 7 (35) 100 (53)
d850 Remunerative employment 67 (80) 2.5 22 (100) 2 9 (41) 98 (70)
e310 Immediate family ++ 61 (65) 1 26 (70) 1 8 (41) 95 (57)
ad540 Dressing 75 3 3 81
d4 mobility 63 (80) 2 5 (30) 0 8 (29) 76 (51)
ae120 Products and technology for
personal indoor and outdoor mobility
and transportation
64 3 3 70
ab710 Mobility of joint functions 55 3 7 65
d920 Recreation and leisure 34 (70) 2 17 (60) 1.5 12 (41) 63 (57)
awere mentioned frequently by fewer than 50% of participants
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for this chapter), followed by Temperament and person-
ality functions (37%). Mobility and Self-Care were the
most common in the category of Activities, with Walk-
ing the most common third-level category affected in
Mobility (29%) and d570 Looking after one’s health --
negative impacts in Self-Care (42%). In the category of
Environmental Factors, Products and Technology and
Support and Relationships were the most common chap-
ters, with e110 Products or substances for personal con-
sumption – facilitator as the most common for the first
(53%) and e355 Health professionals ++ as the most
common for the second (52%).
Discussion
The ICF categories discussed by participants indicate
that the most common bodily impacts of gout for pa-
tients are related to pain. Body structures most affected
were swelling of areas related to movement. Given this,
it is not surprising that the activity described most often
as compromised was mobility, followed by self-care, but
also including major life areas, particularly employment,
domestic life and recreation. The impact of pain and
limits on activity and mobility lead to impairments in
mental and emotional function, as indicated by the num-
ber of references to temperament and emotions.
The frequency of references to categories related spe-
cifically to looking after one’s health under self-care re-
flects that the discussion of gout frequently touched on
what triggered gout flares for participants and how they
attempted to manage these triggers. For an individual
what triggers a gout flare, such as particular foods, may
not be obvious and thus their ability to make healthy
choices is compromised. Also, avoiding enjoyed foods
because they are triggers may be difficult for patients.
The importance of factors related to self-management of
the disease is also reflect in the frequency of meaning
units coded under the (so far unspecified) ‘personal fac-
tors’ category of the ICF.
Environmental factors were an important feature for
participants, both positive and negative – sometimes for
the same category. For example, pharmaceutical treat-
ments for gout were a facilitator for many participants
but for others medication was ineffective or caused un-
pleasant side effects. Another factor was the support of
health professionals, which could act as a facilitator
when it was present, or a barrier when it was not – for
example, lack of communication about the importance
of managing the disease, or failure to refer on to more
specialist care.
There was significant crossover between the frequency
of ICF categories across study locations, but also some
Table 3 Most referenced ICF categories by percentage of participants
number of participants
Name us N = 20 nz N = 10 spain N = 17 All total as % of total participants
e355 Health professionals ++ 20 10 16 46 98%
d570 Looking after one’s health -- negative impacts 19 10 16 45 96%
b280 Sensation of pain 20 10 15 45 96%
e110 Products or substances for personal consumption -- facilitator 19 10 15 44 94%
personal factors 20 10 14 44 94%
d570 Looking after one’s health -- positive impacts 17 10 13 40 85%
e110 Products or substances for personal consumption -- barrier 15 9 11 35 74%
d850 Remunerative employment 16 10 7 33 70%
d450 Walking 20 8 5 33 70%
b126 Temperament and personality functions 19 6 7 32 68%
e310 Immediate family ++ 13 7 7 27 57%
d920 Recreation and leisure 14 6 7 27 57%
b152 Emotional functions 17 8 2 27 57%
b270 Sensory functions related to temperature and other stimuli 13 6 6 25 53%
b770 Gait pattern functions 17 3 5 25 53%
s750 Structure of lower extremity 16 2 6 24 51%
d4 mobility 16 3 5 24 51%
d455 Moving around 19 2 2 23 49%
e355 Health professionals -- 3 7 12 22 47%
d activities 16 1 5 22 47%
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differences. It is a limitation of the study that such dif-
ferences cannot be attributed to local culture but may
have been influenced by the research protocol used in
each location. Yet, the diversity of these patient groups
and the large sample size is also one of the strengths of
this study.
That this study was a secondary analysis of existing
qualitative data is a limitation, as control could not be
exercised over the collection of information to cover the
ICF comprehensively with each participant. Different re-
search objectives for each study meant that although
there was a large quantity of data that was elicited in an
unbiased manner, not all of it was relevant to the ICF.
There are also issues combining studies with different
methodologies – methodology is used to establish rigour
and concepts such as ‘data saturation’, that indicate
when the sample size is appropriate for the study. Be-
cause this concept was not under our control, the data
was possibly ‘oversaturated’ – leading to excessive men-
tions of particular concepts while not reflecting the di-
versity of the experience of gout.
Nearly all the data coding was done by a single obser-
ver. This is acknowledged as a significant limitation, as
the coding reliability cannot be calculated. However, it
did mean that coding was consistent across the 3 data
sources.
The concepts elicited from patients in these various
studies cohere with previous investigations of the impact
of gout on the life of patients, particularly the impact of
affected lower limbs on mobility and other activities and
taking time off work (3,4). Kool et al. found that out-
come studies particularly failed to assess the ICF compo-
nents of ‘Activity and participation’ and ‘Environmental
factors’, both of which were found to be particularly
relevant to participants in this study (8). The results of
this study contribute to the process of developing an
ICF Core Set for gout (7,8).
Conclusions
In this multi-country qualitative study, we found that a
large number of ICF categories are relevant to people
with gout. Pain and personal factors are the most fre-
quently mentioned ICF categories by people with gout.
Environmental factors are also frequently relevant in-
cluding dietary and other triggers, and the role of health
professionals. The results of this study will contribute to
the process of developing an ICF Core Set for gout.
Table 4 Distribution of affected ICF categories
Number of instances % of total
referencesUS NZ Spain All
b1 CHAPTER 1 MENTAL FUNCTIONS 347 23 11 381 10%
b2 CHAPTER 2 SENSORY FUNCTIONS AND PAIN 542 54 52 648 17%
b5 CHAPTER 5 FUNCTIONS OF THE DIGESTIVE, METABOLIC AND ENDOCRINE SYSTEMS 9 8 1 18 0%
b7 CHAPTER 7 NEUROMUSCULOSKELETAL AND MOVEMENT-RELATED FUNCTIONS 94 7 13 114 3%
Total 1161 30%
s7 CHAPTER 7 STRUCTURES RELATED TO MOVEMENT 164 9 11 184 5%
s8 CHAPTER 8 SKIN AND RELATED STRUCTURES 20 2 4 26 1%
Total 210 5%
d2 CHAPTER 2 GENERAL TASKS AND DEMANDS 44 3 3 50 1%
d4 CHAPTER 4 MOBILITY 521 44 25 590 15%
d5 CHAPTER 5 SELF-CARE 335 137 98 570 15%
d6 CHAPTER 6 DOMESTIC LIFE 100 0 0 100 3%
d7 CHAPTER 7 INTERPERSONAL INTERACTIONS AND RELATIONSHIPS 12 8 7 27 1%
d8 CHAPTER 8 MAJOR LIFE AREAS 72 27 11 110 3%
d9 CHAPTER 9 COMMUNITY, SOCIAL AND CIVIC LIFE 48 17 12 77 2%
Total 1524 39%
e1 CHAPTER 1 PRODUCTS AND TECHNOLOGY 325 74 61 460 12%
e3 CHAPTER 3 SUPPORT AND RELATIONSHIPS 171 161 92 424 11%
e4 CHAPTER 4 ATTITUDES 25 57 19 101 3%
e5 CHAPTER 5 SERVICES, SYSTEMS AND POLICIES 10 19 14 43 1%
Total 1028 26%
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According to the development process recommended
by the ICF Research Branch, further research necessary
to identify a core-set of ICF categories for gout are: (1)
application of the generic ICF Checklist (https://www.
who.int/classifications/icf/icfchecklist.pdf?ua=1) list of
categories to patients with gout and (2) a consensus
workshop of relevant stakeholders to consider all the
data from preceding empirical research and to formulate
the final core-set.
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